REFERENCES
- Fekadu, G., Bekele, F., Tolossa, T., Fetensa, G., Turi, E., Getachew,
M., et al. 2021. Impact of COVID-19 pandemic on chronic diseases care
follow-up and current perspectives in low resource settings: a
narrative review. Int J Physiol Pathophysiol Pharmacol. 13:86-93.
- Palmer, K., Monaco, A., Kivipelto, M., Onder, G., Maggi, S., Michel,
J.P., et al. 2020. The potential long-term impact of the COVID-19
outbreak on patients with non-communicable diseases in Europe:
consequences for healthy ageing. Aging Clin Exp Res. 32:1189-1194.
- Kahaly, G.J., Bartalena, L., Hegedüs, L., Leenhardt, L., Poppe, K.,
and Pearce, S.H. 2018. European Thyroid Association Guideline for the
Management of Graves’ Hyperthyroidism. Eur Thyroid J. 7:167-186.
- Ippolito, S., Cusini, C., Lasalvia, P., Gianfagna, F., Veronesi, G.,
Gallo, D., et al. 2021. Change in newly diagnosed Graves’ disease
phenotype between the twentieth and the twenty-first centuries:
meta-analysis and meta-regression. J Endocrinol Invest. 44:1707-1718.
Bartalena, L., and Fatourechi, V. 2014. Extrathyroidal manifestations
of Graves’ disease: a 2014 update. J Endocrinol Invest. 37:691-700.
Schwartz, K.M., Fatourechi, V., Ahmed, D.F., and Pond, G.R. 2002.
Dermopathy of Graves’ disease (pretibial myxedema): long term outcome.
J Clin Endocrinol Metab. 87:438–446.